Anti-Alzheimer's drug lecanemab

Anti-Alzheimer's drug lecanemab

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., attends a press conference in Tokyo on Dec. 13, 2023, as the company's anti-Alzheimer's drug lecanemab is set to be launched on Dec. 20, following a health ministry advisory body's approval of its coverage by the Japanese public insurance scheme.

  • Product Code
  • ILEA002090397
  • Registered date
  • 2023/12/13 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2023 Kyodo News
  • Media size
  • 2599 × 3968 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 685.34(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Tokyo man in 30s being tested for possible Ebola infection

    Tokyo man in 30s being tested for possible Ebola infection

    TOKYO, Japan - Kensuke Nakajima, a senior health ministry official, announces at a press conference in Tokyo, Japan, on Dec. 29, 2014, that a man in his 30s in the capital is being tested for possible Ebola infection after he developed a fever in the early morning on the same day, following his return to Japan from Sierra Leone earlier in December.
      Tokyo man in 30s being tested for possible Ebola infection

      Tokyo man in 30s being tested for possible Ebola infection

      TOKYO, Japan - Kensuke Nakajima, a senior health ministry official, announces at a press conference in Tokyo, Japan, on Dec. 29, 2014, that a man in his 30s in the capital is being tested for possible Ebola infection after he developed a fever in the early morning on the same day, following his return to Japan from Sierra Leone earlier in December.
        Takeda chief apologizes over data misuse in drug ad

        Takeda chief apologizes over data misuse in drug ad

        TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa apologizes during a press conference in Tokyo on March 3, 2014, over an advertisement for the company's blood pressure-lowering drug that made it appear the product is more powerful in suppressing diseases than other medicines.
          Takeda chief apologizes over data misuse in drug ad

          Takeda chief apologizes over data misuse in drug ad

          TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa apologizes during a press conference in Tokyo on March 3, 2014, over an advertisement for the company's blood pressure-lowering drug that made it appear the product is more powerful in suppressing diseases than other medicines.
            Novartis Pharma

            Novartis Pharma

            TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.
              Takeda to acquire Swiss drugmaker

              Takeda to acquire Swiss drugmaker

              TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa makes an announcement at a press conference in Tokyo on May 19, 2011. The largest Japanese drugmaker has signed an agreement with the shareholders of Swiss drugmaker Nycomed S/A to acquire all shares in the Swiss firm for 9.6 billion euros (about 1 trillion yen).
                Settlement plan for Iressa drug damages suits rejected

                Settlement plan for Iressa drug damages suits rejected

                TOKYO, Japan - Japanese health minister Ritsuo Hosokawa announces the government's decision to reject a court settlement plan for damages suits over side effects caused by the lung cancer drug Iressa in a press conference at the ministry in Tokyo on Jan. 28, 2011.
                  Japan declares outbreak of new flu after WHO action

                  Japan declares outbreak of new flu after WHO action

                  TOKYO, Japan - Japanese health minister Yoichi Masuzoe speaks at a press conference at the Ministry of Health, Labor and Welfare on April 28. The minister declared the outbreak of a new influenza following the World Health Organization's upgrading of its alert level.
                    Drugmaker Kowa, Israel's Teva plan joint generic drug firm

                    Drugmaker Kowa, Israel's Teva plan joint generic drug firm

                    TOKYO, Japan - Shlomo Yanai (L), president and chief executive officer of Israel's Teva Pharmaceutical Industries Ltd., and Yoshihiro Miwa, president of Japanese drugmaker Kowa Co., shake hands during a press conference in Tokyo on Sept. 24 at which they announced the two companies will set up a joint generic drug company in Tokyo next year.
                      Death toll from anticancer drug rises to over 100 in Japan

                      Death toll from anticancer drug rises to over 100 in Japan

                      TOKYO, Japan - Nearly 500 people experienced debilitating side effects from an anticancer British-made drug called Iressa (in file photo), resulting in more than 100 deaths in Japan, the Ministry of Health, Labor and Welfare said Dec. 25. As of Dec. 13, of the 358 people who experienced side effects such as pneumonia and lung damage, 114 died, the ministry said.